Linked Life Data

7069930

Source:http://linkedlifedata.com/resource/pubmed/id/7069930

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1982-6-24
pubmed:abstractText
A clinical trial with a special emphasis on anaerobic infections was designed for evaluation of the efficacy, safety, and patient tolerance of cefoxitin. Of the 35 patients who clinically evaluated, 19 had intrareproductive organ infections, 8 had extrareproductive organ infections and 8 had urinary tract infections. Twenty-nine out of the 35 (82.9%) responded satisfactorily to therapy with cefoxitin. The daily dose of cefoxitin for the 35 adult patients (ages ranged from 17 to 62 years) were 1--6 g. There were no adverse systemic reactions, nor was any renal or hematologic toxicity noted. Antibacterial activity tests demonstrated that cefoxitin was active against anaerobic bacteria, especially Bacteroides fragilis. Cefoxitin is thought to be the drug of choice in the treatment of obstetric and gynecologic infections.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0368-2781
pubmed:author
pubmed:issnType
Print
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
189-201
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:year
1982
pubmed:articleTitle
[Clinical findings of cefoxitin in the treatment of obstetric and gynecological infections (author's transl)].
pubmed:publicationType
Journal Article, Comparative Study, English Abstract